EIDX News and Press, Eidos Therapeutics Inc. From 07/22/19

Bridgebio Pharma (NASDAQ: BBIO ) initiated with Buy rating and $42 (53% upside) price target at Goldman Sachs. Initiated with Buy rating and $38 price target at Jefferies. Initiated with Outperform rating and $49 price target at BMO. Initiated with Outperform rating and $34 price target at S...

This is a special contribution article by Prof. Grant Henning based on his published research on the BLM technical theory . The model, his trailing stop-loss approach, and comments are expressly based on his own proprietary methodology and forecasts in the references below. The Bounce/Lag...

Insider buying declined for the third week in a row with insiders purchasing $54.38 million of stock last week compared to $58.39 million in the week prior. Selling also decreased with insiders selling $613.73 million of stock last week compared to $704.94 million in the week prior. Sell/Bu...

Quick Take BridgeBio ( BBIO ) has filed to raise gross proceeds of up to $225 million from a U.S. IPO, according to an S-1/A registration statement . The group is developing therapeutics for Mendelian diseases, or diseases arising from defects in a single gene as well as cancers with clea...

SAN FRANCISCO, June 18, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX ) today announced that management will participate in a fireside chat at the 2019 BMO Prescriptions for Success Healthcare Conference on Tuesday, June 25 th at 2:40 p.m. EDT in New York, NY. ...

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 05/15/2019. Please visit our Tracking Ole Andreas Halvorsen...

Insider buying increased last week against the backdrop of a weak market with insiders purchasing $214.72 million of stock compared to $158.64 million in the week prior. Selling, on the other hand, decreased with insiders selling $1.25 billion of stock last week compared to $2.03 billion in th...

BridgeBio ( BBIO ) is a different breed of biotech IPO. It approaches the biotech business with what feels like seed-and-feed approach. Seeding a number of highly interesting and promising early stage programs and working closely with the experts behind them to take it through the journey to...

"A diplomatic statement ... is a statement of which everything is true but the sentiment which seems to prompt it .” ― Joseph Conrad, Victory My regular readers know I rarely look at new IPOs until they are public for at least 18 months. So many of these small cap names, esp...

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...